Collaboration
The UK biotech Vernalis and Servier, France’s largest privately-owned pharmaceutical company, have signed a new three-year joint oncology collaboration, focused on the discovery of drugs for a new (undisclosed) target.
Under the terms of the collaboration, which uses Vernalis’ proprietary fragment and structure-based drug discovery platform on this undisclosed cancer target, Vernalis will receive fees and a share in the downstream success of any product in the form of milestones and royalties on sales, the terms of which are not disclosed.
The two companies have an existing agreement to develop two oncology targets involved in protein-protein interactions. Ian Garland, CEO of Vernalis, said, “This latest collaboration confirms our excellent working relationship and Servier’s recognition of the quality of our fragment and structure-based drug discovery platform.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
